Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.
Profitability
This table compares Verrica Pharmaceuticals and 60 Degrees Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Verrica Pharmaceuticals | -189.23% | -275.64% | -101.96% |
| 60 Degrees Pharmaceuticals | -650.21% | N/A | -136.81% |
Analyst Ratings
This is a summary of recent recommendations for Verrica Pharmaceuticals and 60 Degrees Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Verrica Pharmaceuticals | 1 | 1 | 3 | 0 | 2.40 |
| 60 Degrees Pharmaceuticals | 1 | 2 | 1 | 0 | 2.00 |
Verrica Pharmaceuticals currently has a consensus target price of $12.67, suggesting a potential upside of 295.83%. 60 Degrees Pharmaceuticals has a consensus target price of $13.85, suggesting a potential upside of 2,615.69%. Given 60 Degrees Pharmaceuticals’ higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Verrica Pharmaceuticals.
Valuation & Earnings
This table compares Verrica Pharmaceuticals and 60 Degrees Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Verrica Pharmaceuticals | $35.58 million | 1.55 | -$17.89 million | ($2.22) | -1.44 |
| 60 Degrees Pharmaceuticals | $1.41 million | 1.27 | -$7.36 million | ($4.82) | -0.11 |
60 Degrees Pharmaceuticals has lower revenue, but higher earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Verrica Pharmaceuticals has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.47, indicating that its share price is 147% more volatile than the S&P 500.
Institutional and Insider Ownership
42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Verrica Pharmaceuticals beats 60 Degrees Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
About Verrica Pharmaceuticals
Verrica Pharmaceuticals is a dermatology-focused biopharmaceutical company that develops and commercializes treatments for skin diseases. The company is based in West Chester, Pennsylvania, and its activities include both marketed products and investigational therapies. Its FDA-approved product, YCANTH, is a topical cantharidin treatment for molluscum contagiosum in adults and children ages 2 and older. The treatment is applied by a healthcare professional. Verrica is also developing therapies for other skin conditions.
About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for infectious diseases, particularly malaria and other parasitic infections. Its portfolio includes tafenoquine, an antimalarial medicine marketed in the United States as ARAKODA for the prevention of malaria in adults. The company is also studying tafenoquine for potential use against babesiosis, a tick-borne parasitic disease. These development programs are investigational; tafenoquine’s approval for malaria prevention does not extend to babesiosis.
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
